TABLE OF CONTENTS

In This Issue/Research Watch/News-in-Brief/News from the IASLC Tobacco Control Committee .................................................................147

EDITORIALS

Take a Look at Clinical Data in Detail, Analyze Them, and Develop a New Diagnostic Method.................................................................158
Takeshi Johkoh, MD, PhD

Is Darbepoietin Alfa Linked to Mortality During Non–Small Cell Lung Cancer Chemotherapy?...............................................................159
Jean-Louis Pujol, MD, PhD and Benoit Roch, MD

Blood-Based Disease Assessment in SCLC: A Perpetual Proof of Concept or a Clinically Important Tool? ..................................................163
Jacob M. Sands, MD, Marina S. D. Milan, BA, and Geoffrey R. Oxnard, MD

Combination of Immunotherapy and Radiotherapy—The Next Magic Step in the Management of Lung Cancer? ...............................166
Lizza E. L. Hendriks, MD, PhD, Jessica Menis, MD, Dirk K. M. De Ruyscher, MD, PhD, and Martin Reck, MD

About the Cover: the cover image is from Figure 2A & 2B in the article by Mohan et al. on page 216.

Chr   1                       3                  5                 7              9            11          13       15      17    19   21

ES-SCLCLS-SCLCControls

PGA Z-Score MI

0   40  80  0   40000   0.0   0.4     0.8

1

0

26

01

0

0

PGA 90% (27/30)

ZS 87% (26/30)

MI  90% (27/30)

ALL 93% (28/30)

ES-SCLC = 30

PGA 74% (29/29)

ZS 74% (29/39)

MI  74% (29/39)

ALL  77% (30/39)

LS-SCLC = 39

PGA 81% (56/69)

ZS 80% (55/69)

MI  81% (56/69)

ALL  84% (58/69)

ALL SCLC = 69

E denotes online only article

OPEN ACCESS denotes Open Access article

(continued on next page)
EDITORIAL: LUNG CANCER WORLDWIDE

Lung Cancer in Brazil ................................................................................................................................. 170
Clarissa Mathias, MD, PhD, Gustavo Faibischew Prado, MD, PhD,
Eldsmaria Mascarenhas, MD, Paula Antonia Ugalde, MD,
Ana Carolina Zimmer Gelatti, MD, Elizangela Santos Carvalho, MD,
Lilian Dantonino Faroni, MD, MSc, Ricardo Oliveira, MD,
Vladimir Claudio Cordeiro de Lima, MD, PhD, and Gilberto de Castro Jr., MD, PhD,
on behalf of the Grupo Brasileiro de Oncologia Torácica

REVIEW ARTICLE

Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage NSCLC ................................................................................................................................. 176
Eric D. Brooks, MD, MHS, Vivek Verma, MD, Suresh Senan, MD, Thierry De Baere, MD,
Shun Lu, MD, Alessandro Brunelli, MD, and Joe Y. Chang, MD, PhD, on behalf of the
International Association for the Study of Lung Cancer Advanced Radiation Technology Committee

ORIGINAL ARTICLES

Quality of Life

OPEN ACCESS A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC................................................................................................................................. 190
Pere Gascón, MD, PhD, Rajnish Nagarkar, M.B.B.S., MS, Martin Šmakal, MD,
Konstantinos N. Syrigos, MD, PhD, Carlos H. Barrios, MD, Jesús Cárdenas Sánchez, MD,
Li Zhang, MD, David H. Henry, MD, David Gordon, MD, Vera Hirsh, MD, FRCPC,
Kaoru Kubota, MD, PhD, Sergey Orlov, MD, PhD, Gary Thomas, MD,
Tilman Steinmetz, MD, Jin-Hyoung Kang, MD, PhD, Dianne K. Tomita, MPH,
Alexander N. Fleishman, MS, Joseph K. Park, MD, PhD, and
Cisio De Oliveira Brandao, MD, MBA, MsC

Translational Oncology

A Novel Algorithm to Differentiate Between Multiple Primary Lung Cancers and Intrapulmonary Metastasis in Multiple Lung Cancers With Multiple Pulmonary Sites of Involvement................................................................................................. 203
Young Joo Suh, MD, PhD, Hyun-Ju Lee, MD, PhD, Pamela Sung, MD, Heera Yoen, MD,
Sewoo Kim, MD, Seungchul Han, MD, Sungun Park, MD, Jung Hee Hong, MD,
Heekyung Kim, MD, Jiyeon Lim, MD, Hyungjin Kim, MD, PhD,
Soon Ho Yoon, MD, PhD, Yoon Kyung Jeon, MD, PhD, and Young Tae Kim, MD, PhD

OPEN ACCESS Profiling of Circulating Free DNA Using Targeted and Genome-wide Sequencing in Patients with SCLC ................................................................................................. 216
Sumitra Mohan, PhD, Victoria Foy, MD, Mahmood Ayub, PhD, Hui Sun Leong, PhD,
Pieta Schofield, PhD, Sudhakar Sahoo, PhD, Tine Descamps, PhD, Bedirhan Kilerci, MSc,
Nigel K. Smith, BSc, Mathew Carter, BSc, Lynsey Priest, MSc, Cong Zhou, PhD,
T. Hedley Carr, PhD, Crispin Miller, PhD, Corinne Fairvre-Finn, FRCP, MD, PhD,
Fiona Blackhall, FRCP, PhD, Dominic G. Rothwell, PhD, Caroline Dive, PhD, and
Gerard Brady, PhD

(continued on next page)
SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas

Natasha Rekhtman, MD, PhD, Joseph Montecalvo, MD, Jason C. Chang, MD, Deepu Alex, MD, PhD, Ryan N. Ptashkin, MS, Ni Ai, PhD, Jennifer L. Sauter, MD, Brie Kezlarian, MD, Achim Jungbluth, MD, PhD, Patrice Desmeules, MD, MS, Amanda Beras, BA, Justin A. Bishop, MD, Andrew J. Plodkowski, MD, Mrital M. Gounder, MD, Adam J. Schoenfeld, MD, Azadeh Namakypou, MD, MS, Bob T. Li, MD, MPH, Charles M. Rudin, MD, PhD, Gregory J. Riely, MD, PhD, David R. Jones, MD, Marc Ladanyi, MD, and William D. Travis, MD

Non-Small Cell Lung Cancer

Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC

Steven H. Lin, MD, PhD, Yan Lin, RN, Luyang Yao, MS, Neda Kalhor, MD, Brett W. Carter, MD, Mehmet Altan, MD, George Blumenschein, MD, Lauren A. Byers, MD, MS, Frank Fossella, MD, Don L. Gibbons, MD, PhD, Jonathan M. Kurie, MD, Charles Lu, MD, George Simon, MD, Ferdinandas Skoulidis, MD, Joe Y. Chang, MD, PhD, Melenda D. Jeter, MD, Zhongxing Liao, MD, Daniel R. Gomez, MD, Michael O’Reilly, MD, Vali Papadimitrakopoulou, MD, Peter Thall, PhD, John V. Heymach, MD, PhD, and Anne S. Tsao, MD

Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors

Jessica J. Lin, MD, Adam J. Schoenfeld, MD, Viola W. Zhu, MD, PhD, Beow Y. Yeap, ScD, Emily Chin, BA, Margarette Rooney, BA, Andrew J. Plodkowski, MD, Subba R. Digumarthy, MD, Ibiayi Dagogo-Jack, MD, Justin F. Gainor, MD, Sai-Hong Ignatius Ou, MD, PhD, Gregory J. Riely, MD, PhD, and Alice T. Shaw, MD, PhD

Small Cell Lung Cancer

Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer

James W. Welsh, MD, John V. Heymach, MD, PhD, Dawei Chen, MD, Vivek Verma, MD, Taylor R. Cushman, BS, Kenneth R. Hess, PhD, Girish Shroff, MD, Chad Tang, MD, Ferdinandas Skoulidis, MD, Melinda Jeter, MD, Hari Menon, BS, Quynh-Nhu Nguyen, MD, Joe Y. Chang, MD, PhD, Mehmet Altan, MD, Vassiliki A. Papadimitrakopoulou, MD, George R. Simon, MD, Uma Raju, MD, Lauren Byers, MD, and Bonnie Glisson, MD

Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses

Taofeek K. Owonikoko, MD, Huifeng Niu, PhD, Kristianna Nackaerts, MD, PhD, Tibor Csoszi, MD, Gyula Ostoros, MD, Zsuzsanna Mark, MD, Christina Baik, MD, MPH, Anil Abraham Joy, MD, Christos Chouaid, MD, Jesus Corral Jaime, MD, Vitezslav Kolek, MD, PhD, Margarita Majem, MD, PhD, Jaromir Roubec, MD, PhD, Edgardo S. Santos, MD, FACP, Anne C. Chiang, MD, PhD, Giovanna Speranza, MD, Chandra P. Belani, MD, Alberto Chiappori, MD, Manish R. Patel, MD, Kritzhina Czebe, MD, Lauren Byers, MD, Brittany Bahamnon, BSc, Cong Li, PhD, Emily Sheldon-Waniga, PhD, Eric F. Kong, PhD, Miguel Williams, MS, Sunita Badola, MSc, Hyunjin Shin, PhD, Lisa Bedford, MSc, Jeffrey A. Ecsedy, PhD, Matthew Bryant, BSc, Sian Jones, PhD, John Simmons, PhD, E. Jane Leonard, MSc, Claudio Dansky Ullmann, MD, PhD, and David R. Spigel, MD, on behalf of the CI4018 study investigators

(continued on next page)
TABLE OF CONTENTS (continued)

BRIEF REPORT

OPEN ACCESS Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC .............. 288
Jhanelle E. Gray, MD, Augusto Villegas, MD, Davey Daniel, MD, David Vicente, MD, Shiji Murakami, MD, Rina Hui, MD, Takayasu Kurata, MD, Alberto Chiappori, MD, Ki Hyeong Lee, MD, Byoung Chul Cho, MD, David Planchard, MD, Luis Paz-Ares, MD, Corinne Faivre-Finn, MD, Johan F. Vansteenkiste, MD, David R. Spigel, MD, Catherine Wadsworth, BVSc, Maria Taboada, MSc, Phillip A. Dennis, MD, Mustafa Ozgüroğlu, MD, and Scott J. Antonia, MD

LETTERS TO THE EDITOR

© STRN3-NTRK1: A Novel NTRK1 Oncogenic Fusion in a Patient with Lung Adenocarcinoma................................................................. e23
Rongguo Lu, MD, Chuang Qi, MD, Mingzhe Xiao, PhD, Shangli Cai, PhD, and Mingfeng Zheng, MD

© Intracardiac Involvement by Primary Malignant Mesothelioma: A Report of Two Cases ................................................................. e25
Michel S. Kabbash, BS, Joseph Edmund, MD, Azam Ghafoor, MD, Raafit Hassan, MD, Douglas Rosing, MD, and Anish Thomas, MD

© A Novel Oncogenic RELCH-Ret Fusion Variant in Non–Small Cell Lung Cancer: RELCH-RET................................. e27
Huachi Jiang, MS, Mingzhe Xiao, PhD, Chuang Qi, PhD, Shangli Cai, PhD, MD, and Feng Liu, PhD

© Eosinophilic Fasciitis Triggered by Nivolumab: A Remarkable Efficacy of the mTOR Inhibitor Sirolimus.............................................. e29
Erwan Le Tallec, MD, Alain Lescoat, MD, Alice Ballere, MD, Bérengère Cador, MD, Hervé Lena, MD, Charles Ricordel, MD, Sène Damien, MD, PhD, Céleste Lebbe, MD, PhD, Patrick Jego, MD, PhD, and Nicolas Belhomme, MD